Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer

BACKGROUND: Most patients with small-cell lung cancer (SCLC) experience disease progression after first-line chemotherapy. Notably, nab-paclitaxel monotherapy has antitumor activity in relapsed SCLC. OBJECTIVE: This study evaluated the efficacy and safety of combined of nab-paclitaxel and immune che...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Rui, Guo, Yanrong, Hao, Xuezhi, Wang, Zhijie, Duan, Jianchun, Wang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302613/
https://www.ncbi.nlm.nih.gov/pubmed/37389188
http://dx.doi.org/10.1177/17588359231179315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302613/
https://www.ncbi.nlm.nih.gov/pubmed/37389188
http://dx.doi.org/10.1177/17588359231179315

Ejemplares similares